Elvin Zengin

Elvin Zengin

Auto-generated profile, based on publicly available information

Elvin Zengin

University Heart and Vascular Center Hamburg , Hamburg , Germany

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2015 in Biomarkers in Medicine
Verified
Journal Article
Closed access
EZElvin Zengin
Elvin Zengin
Christoph SinningChristoph Sinning
Christoph Sinning
TZTanja Zeller
Tanja Zeller
HRHans-J Rupprecht
Hans-J Rupprecht
RSRenate B Schnabel
Renate B Schnabel
FIfor the AtheroGene Study investigators
for the AtheroGene Study investigators
Background: Pregnancy-associated plasma protein-A (PAPP-A) is discussed as a biomarker representing unstable plaques in coronary artery disease (CAD). Methods: In this study 927 patients with CAD (534 with stable angina and 393 with acute coronary syndrome [ACS]) and 217 patients without CAD and measured PAPP-A levels were included. Follow-up for a median of 5 years was documented. Results: Rising quartiles of PAPP-A concentration had a higher cardiovascular mortality in the overall cohort of patients with CAD (p = 0.002) and the cohort with ACS (p = 0.01). Patients with suspected ACS below the LOD for troponin I but elevated PAPP-A levels had an increased cardiovascular mortality. A cut-off of 11.4 IU/l identified patients with a higher mortality during follow-up. Conclusion: Rising PAPP-A levels are prognostic in patients with CAD. PAPP-A levels were especially predictive in ACS patients with troponin below 10% CV of the 99th percentile for cardiovascular mortality.

1 April 2021 in Cardiovascular Diagnosis and Therapy
Verified
Journal Article
Open access
PDF file
EZElvin Zengin
Elvin Zengin
CSChristoph Sinning
Christoph Sinning
CBChristopher Blaum
Christopher Blaum
SBStefan Blankenberg
Stefan Blankenberg
CRCarsten Rickers
Carsten Rickers
VSVictoria M. Stoll
Victoria M. Stoll
The number of adults with congenital heart disease (ACHD) has increased over the last decades due to advancements in medical care, including interventional and surgical therapies. We are therefore more frequently challenged by the long-term consequences of palliative or corrective surgery carried out during childhood. Although patients with ACHD may develop conditions related to general cardiovascular risk factors, such as coronary artery disease, the most common complications leading to morbidity and mortality are arrhythmias, heart failure and thromboembolic events. For the management of arrhythmias, current recommendations regarding ablation and device therapy must be considered, whilst also taking into account the anatomical limitations of their congenital heart defect or surgical pathways. Heart failure treatment in acute and chronic settings must also consider the particular anatomy present, including the nature of the systemic ventricle. Treatments strategies for ACHD are typically extrapolated from the respective guidelines in non-ACHD patients, despite a lack of evidence to support this strategy. Right heart failure can be especially challenging to manage in conditions where either a systemic right ventricle or shunt lesions resulting in volume and/or pressure loading of the right ventricle are present. All physicians and cardiologists in particular should be acquainted with the most common diseases in ACHD, their complications and management regime, especially with regards to heart failure as this is a common reason for acute presentation in the emergency department.

1 December 2021 in Cardiovascular Diagnosis and Therapy
Verified
Journal Article
Open access
PDF file
BTBetül Toprak
Betül Toprak
KGKatharina Govorov
Katharina Govorov
KKKatinka Kurz
Katinka Kurz
DCDora Csengeri
Dora Csengeri
JWJessica Weimann
Jessica Weimann
EZElvin Zengin-Sahm
Elvin Zengin-Sahm
Outcome of pregnancy in a contemporary cohort of adults with congenital heart disease—a 10-year, single-center experience Betül Toprak, Katharina Govorov, Katinka Kurz, Dora Csengeri, Jessica Weimann, Dennis Witte, Kurt Hecher, Bettina Hollwitz, Anne Hansen, Carsten Rickers, Christina Magnussen, Yskert von Kodolitsch, Tanja Zeller, Stefan Blankenberg, Christoph Sinning, Paulus Kirchhof, Elvin Zengin-Sahm

1 October 2019 in Cardiovascular Diagnosis and Therapy
Verified
Journal Article
Closed access
PDF file
EZElvin Zengin
Elvin Zengin
GMGötz Mueller
Götz Mueller
SBStefan Blankenberg
Stefan Blankenberg
YKYskert von Kodolitsch
Yskert von Kodolitsch
CRCarsten Rickers
Carsten Rickers
CSChristoph Sinning
Christoph Sinning
Congenital heart disease (CHD) is present in 0.8–0.9% of live births. Prevalence of CHD is constantly increasing during the last decades in line with the treatment options for patients ranging from the surgical as well to the interventional spectrum. Most of the women with underlying CHD reach adulthood due to excellent surgical and interventional treatment options and most of them desire pregnancy. In Western countries, maternal heart disease is the major cause of mortality during pregnancy, thus risk estimation should be therefore individualized depending on the underlying CHD, functional class and treatment options. Pre-pregnancy counselling is mandatory in all women, especially in patients with high risk but even in patients with low risk, a plan for labor and delivery should be outlined in a heart pregnancy team. This review addresses the key element of pre-counselling, planning and successful disease management in patients with CHD during pregnancy.

15 April 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BTBetül Toprak
Betül Toprak
KSKatalin Szöcs
Katalin Szöcs
EZElvin Zengin-Sahm
Elvin Zengin-Sahm
Christoph SinningChristoph Sinning
Christoph Sinning
AHAmra Hot
Amra Hot
YKYskert von Kodolitsch
Yskert von Kodolitsch
Pregnancy poses a threat to women with aortopathy. Conclusive data on the obstetric and aortic outcome in this risk collective, especially when it comes to aortic complications in the long term, are still missing. This study offers a comparative analysis of pregnancy-associated outcome in 113 consecutive women with Marfan syndrome or bicuspid aortic valve disease, including 46 ever-pregnant and 37 never-pregnant women with Marfan syndrome, and 23 ever-pregnant and 7 never-pregnant females with bicuspid aortic valve disease. The overall obstetric outcome was comparable between ever-pregnant women with Marfan syndrome and with bicuspid aortic valve disease (p = 0.112). Pregnancy-associated aortic dissection occurred in two women with Marfan syndrome (3%) during a total of 62 completed pregnancies, whereas no single case of aortic event occurred in women with bicuspid aortic valve disease during a total of 36 completed pregnancies (p = 0.530). In the long-term follow-up, aortic dissection occurred in 21% of ever-pregnant women with Marfan syndrome, but in none of the women with bicuspid aortic valve disease (p = 0.022). Proximal aortic surgery was performed with similar frequency in ever-pregnant women with Marfan syndrome and with bicuspid aortic valve disease in the long term (p = 0.252). However, ever-pregnant women with Marfan syndrome were younger when surgery was performed (44 ± 9 vs. 59 ± 7 years; p = 0.041). In Marfan syndrome, long-term growth of the aorta was comparable between ever-pregnant and never-pregnant women. Pregnancy thus exhibited an increased immediate aortic risk only in women with Marfan syndrome, but not in women with bicuspid aortic valve disease. Previous pregnancy did not relate to an increased long-term risk of adverse aortic events in women with Marfan syndrome or with bicuspid aortic valve disease.

1 January 2016 in International Journal of Cardiology
Verified
Journal Article
Closed access
EZE. Zengin
E. Zengin
CSC. Sinning
C. Sinning
BSB. Schrage
B. Schrage
GMG.C. Mueller
G.C. Mueller
HKH. Klose
H. Klose
RKR. Kozlik-Feldmann
R. Kozlik-Feldmann